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ABSTRACT
Theaggregateofepidemiologicalstudiesindicatesasignif-
icantly elevated risk for cancer in people with a high body
massindex(BMI);a“dose–response”effectexistswithin-
creasing risk as BMI increases from the normal to over-
weighttoobesecategories.Successfulsustainedweightloss
decreasesfuturerisk.Therelationshipofbeingoverweight
to the risk for leukemia in the aggregate has been sup-
ported in several large cohort studies and two meta-anal-
ysesofcohortandcase–controlstudies.Onemeta-analysis
found an elevated risk for each of the four major subtypes
of leukemia. A significant association between the risk for
non-Hodgkin’s lymphoma and elevated BMI was sup-
ported by a meta-analysis of 13 cohort and nine case–
controlstudies.TheriskfordiffuselargeB-celllymphoma
may be especially significant. A high BMI increases the
risk for myeloma, as judged by a meta-analysis of 11 co-
hort and four case–control studies. The biological rela-
tionship of obesity to the risk for cancer (biological
plausibility) is unresolved. The two major causal final
pathways could be “inductive” or “selective.” The meta-
bolic, endocrinologic, immunologic, and inflammatory-
like changes resulting from obesity may increase the cell
mutationrate,dysregulategenefunction,disturbDNAre-
pair, or induce epigenetic changes, favoring the induction
of neoplastic transformation (inductive). Alternatively,
obesity may create an environment in which pre-existing
clones that are dormant are permitted (selected) to
emerge. The Oncologist 2010;15:1083–1101
INTRODUCTION
TheprevalenceofobesityintheU.S.hasincreased,atleast,
over the last several decades. The National Health and Nu-
trition Examination Survey, which consists of a nationally
representative sample of men and woman aged 20 years,
indicatesthat,inthe2007–2008sample,33.8%(confidence
interval [CI], 31.6%–36.0%) of Americans were obese as
definedbytheWorldHealthOrganizationcategorization,a
bodymassindex(BMI)30.0kg/m
2.Overweight,defined
as a BMI of 25–29.9 kg/m
2, was present in an additional
34.2% of the population. Thus, 68% of the U.S. population
exceeded the upper limit of normal BMI (18.5–24.9 kg/m
2)
[1]. The World Health Organization has estimated that
1.6 billion people worldwide are overweight, of whom
approximately one quarter are obese.
BMI, with the exception of some heavily muscled ath-
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body fat. In children, BMI is adjusted for differences in
body fat between males and females and for different ages
in childhood. BMI is one of several indicators of body fat
(others include skin-fold thickness, waist circumference,
waist to hip circumference ratio, and several techniques re-
quiringspecialinstrumentsandoperatorexpertise);it,how-
ever, has been accepted as the best and most practical
screening index by the World Health Organization and the
U.S. Public Health Service.
There are differences in rates of obesity among Ameri-
cans of European, African, and Asian ancestry but the cur-
rent prevalence of obesity in each group has increased over
their historical standards. There are minor adjustments in
the definition of overweight and obesity in some areas of
the world. For example, in China, the BMI is about 2 kg/m
2
lower for each body mass category: underweight, normal,
overweight, and obese. Trends indicate a plateau in the
prevalence rate of obesity in the U.S. in women and chil-
dren over the last 10 years and in men over the last 5 years,
according to the Centers for Disease Control and Preven-
tion [2], perhaps indicating the effects of awareness and
changes in eating and exercise habits or an effect in which
the genetically and environmentally susceptible popula-
tions have reached an asymptote, or both.
Using BMI, population studies have established a link
between obesity and several major human cancers (e.g.,
postmenopausal breast, colon, endometrium, esophagus,
liver, and kidney cancers) and strong indications of a link
with others. The role of obesity in cancer incidence and
mortality is thought to be causal because of the consistency
of large cohort studies, the relatively long latency period
observed between the onset of obesity and a subsequent in-
crease in cancer incidence, the evidence for a biologically
plausible relationship in humans among the metabolic, en-
docrinologic, and inflammatory effects of obesity and their
experimental links to cell proliferation and cell survival,
and the early preliminary evidence for a lower incidence of
cancer in women who have had sustained weight loss as a
result of medical or surgical interventions [3, 4]. Here, I re-
view the studies of obesity and the risk for hematological
malignancies.
RISK FOR LEUKEMIA,N ON-HODGKIN’S
LYMPHOMA, AND MYELOMA OBSERVED IN
GENERAL STUDIES OF THE LINK OF OBESITY
TO CANCER
Inaprospectivestudy,theCancerPreventionStudyII,con-
ducted by the American Cancer Society of 900,000 adults
in the U.S. who had no evidence of cancer at enrollment in
1982, there were 57,145 deaths from cancer during a 16-
year follow-up. The death rate from all cancers in members
ofthecohortwithextremeobesity(BMI40.0kg/m
2)was
52% higher for men and 62% higher for women than for
individuals of normal weight. The relative risk (RR) for
death from cancer in this group was 1.52 (CI, 1.13–1.87) in
menand1.62(CI,1.40–1.87)inwomen.TheRRforcancer
increased incrementally for both men and women in rela-
tionship to increasing BMI over the normal upper limit, a
clearcut dose–response relationship for increasing risk for
cancer mortality with increasing BMI [5]. These investiga-
tors used multivariate proportional hazard models to con-
trol for potentially confounding variables such as smoking,
alcohol use, ethnicity, dietary variations, and others, and
concluded that the excess death rates from cancer attribut-
able to overweight (BMI, 25–29.9 kg/m
2) or obesity (BMI
30.0 kg/m
2) were approximately 9% in men and 17% in
women. Of particular interest to this commentary, the RR
formortalityfromnon-Hodgkin’slymphomaandmyeloma
was significantly greater with a significant trend with in-
creasing BMI. In males, for example, the RR associated
with a BMI of 29.9 but 39.9 kg/m
2 for myeloma and
non-Hodgkin’s lymphoma was approximately 1.50; in fe-
males of the same BMI range, the RR was approximately
1.45. Leukemia deaths increased stepwise with increasing
categories of BMI above the normal range, with each step
statistically significant when compared with people with a
normal BMI, for men. The RR for leukemia was 37%
greater in men with a BMI of 30–34.9 kg/m
2. No informa-
tion was provided for major leukemia or lymphoma sub-
types.
In a large cohort of male U.S. military veterans
(3,668,486 whites, 832,214 blacks) hospitalized with a di-
agnosis of obesity in 1969–1996, the authors examined the
risk for cancer at all major cancer [6]. Because of small
numbers, women and ethnicities other than blacks and
whites were excluded from the original number of
5,790,493 veterans discharged during that period. The
specifications for the diagnosis of obesity in the Veterans
Affairs hospital system was defined as receiving a dis-
charge diagnosis coded as 277 according to the eighth revi-
sion of the International Classification of Diseases (ICD8)
or 278 according to the ICD9. The authors calculated age-
and calendar-year–adjusted RRs for cancer among white
and black veterans, comparing obese men with nonobese
men hospitalized for other reasons. For selected cancers,
additional analyses were performed stratified by specific
medical conditions related to both obesity and the risk for
those cancers. Risk was significantly elevated for myeloma
among obese white veterans (RR, 1.22; CI, 1.05–1.40) and
among obese black veterans (RR, 1.26; CI, 1.02–1.56), but
risk was not significantly elevated for Hodgkin’s or other
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(aggregated) among obese white veterans (RR, 1.42; CI,
1.31–1.54) and among obese black veterans (RR, 1.77; CI,
1.45–2.15), for acute myelogenous leukemia among obese
white veterans (RR, 1.59; CI, 1.33–1.90) and among obese
black veterans (RR, 2.64; CI, 1.80–3.85), and for chronic
lymphocytic leukemia among obese white veterans (RR,
1.30; CI, 1.13–1.49) and among obese black veterans (RR,
1.72; CI, 1.24–2.39). In the analysis of chronic myeloge-
nousandacutelymphocyticleukemia,theRRwaselevated,
although not significantly, which may have been related to
a much smaller number of cases, especially of adult acute
lymphocytic leukemia (e.g., one case among obese black
men).
Faculty at the Centre for Chronic Disease Prevention
and Control in Ottawa, Canada did a case–control study of
21,022 incident cases of 19 types of cancers among people
aged 20–76 years during 1994–1997 [7]. This group was
compared with 5,039 control subjects. Individuals with a
BMI 25 kg/m
2 were compared with those with a BMI
25kg/m
2,usingamultivariateadjustedORtoassessrisk.
Thosescientistsestimatedthatexcessbodymassaccounted
for9.7%ofcancersinmalesand5.9%ofcancersinwomen
in Canada. The ORs for overweight men (1.32; CI, 1.07–
1.60) and obese men (1.41; CI, 1.07–1,84) were signifi-
cantly greater for the risk for leukemia (aggregate) than
theywereforoverweightwomen(OR,1.28;CI,1.00–1.65)
and obese women (OR, 2.01; CI, 1.49–2.71). The OR for
the risk for non-Hodgkin’s lymphoma was significantly
greaterinoverweightmen(OR,1.25;CI,1.05–1.48),obese
men (OR, 1.42; CI, 1.12–1.80), and obese women (OR,
1.54; CI, 1.21–1.95). The OR for the risk for myeloma was
significantly higher in overweight men (OR, 1.64; CI,
1.09–2.47), obese men (OR, 2.16; 1.25–3.75), and obese
women (OR, 1.92; CI, 1.23–3.00). Although the risk for
leukemia was elevated in both overweight and obese men
and women, a breakdown among the four major types of
leukemia was not reported. These investigators estimated
that an elevated BMI accounted for about 18% of all leuke-
mias.
Members of the Cancer Epidemiology Unit, University
of Oxford, conducted a study on the relationship between
BMI and incidence and mortality for 17 cancer sites among
1.3 million women, aged 50–64 years, or one in four
women in the U.K. in that age group [8]. They adjusted the
analysis for age, geographical region, socioeconomic sta-
tus, age at first birth, parity, smoking, alcohol intake, phys-
ical activity, years since menopause, and use of hormone
replacement therapy. The results of that study indicate that
about 5% of the cancer incidence in postmenopausal
women in the U.K. is attributable to overweight (BMI,
25.0–29.9 kg/m
2) or obesity (BMI 30 kg/m
2). A signifi-
cant trend of an increasing RR for incidence for each 10-
unit increase in BMI was noted for leukemia (aggregate)
(RR, 1.50), non-Hodgkin’s lymphoma (RR, 1.17), and my-
eloma (RR, 1.31).
ResearchersattheCenterofHealthPromotionandObe-
sity Research and the National Health Insurance Corpora-
tion in South Korea assessed the relationship between BMI
and cancer onset in a 10-year study of 781,283 Korean men
who were cancer free at entry into the cohort [9]. They
foundasignificantassociationbetweenobesityandtherisk
forninecancers,mostofthesefoundinotherstudiesonthis
question, adding strength to the association. Of the hema-
tological malignancies, a barely significant association was
found between BMI and non-Hodgkin’s lymphoma but not
between BMI and leukemia or myeloma.
Investigators at the School of Cancer Studies, Uni-
versity of Manchester, U.K., did electronic searches of
MEDLINE and Embase (1966 to November 2007) to iden-
tify prospective studies of incident cases of 20 cancer types
[10]. They used these data to do a systematic review and
meta-analysistoassessthestrengthofassociationsbetween
BMI and different sites of cancer, between sex and ethnic
groups, and between the risk for cancer and a 5 kg/m
2
greaterBMI.Theyexamined221datasets(141articles),in-
cluding 282,137 incident cases. In men, a 5 kg/m
2 higher
BMI was associated with a modest but significantly higher
risk for leukemia (aggregate) (RR, 1.08; CI, 1.02–1.14),
myeloma (RR, 1.11; CI, 1.05–1.30), and non-Hodgkin’s
lymphoma(RR,1.06;CI,1.03–1.09).Inwomen,theRRfor
leukemia with a 5 kg/m
2 higher BMI was 1.17 (CI, 1.04–
1.32);formyelomaitwas1.11(CI,1.07–1.15)andfornon-
Hodgkin’s lymphoma it was 1.07 (CI, 1.00–1.14). The
association between a higher BMI and the risk for a nonhe-
matological malignancy was generally similar in studies
from North America, Europe and Australia, and the Asia-
Pacific region, but was not reported for hematological ma-
lignancies perhaps because of small numbers after
stratification.
Investigators at the Institute of Environmental Medi-
cine,KarolinskaInstitute,useddatacollectedprospectively
from two Swedish twin cohorts and a Finnish twin cohort
(in total, 70,067 people) to study the effects of overweight
(BMI,25–29.9kg/m
2)andobesity(BMI30kg/m
2)onthe
developmentofleukemia(aggregate),non-Hodgkin’slym-
phoma, Hodgkin’s lymphoma, and myeloma [11]. The co-
horts were followed from baseline through 2002 (Sweden)
orthrough2004(Finland).ThesestudiesfoundahigherRR
for myeloma in the older cohort of twins (RR, 2.1; CI, 1.1–
3.7) and among men and women in both countries. A
greaterRRwasfoundforchronicmyeloidleukemiaamong
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tic leukemia in overweight people (RR, 2.7; CI, 0.8–9.6),
when compared with those with a normal BMI. The latter
CI was wide, however, and the RR for acute lymphoblastic
leukemia,althoughrelativelyhigh,onlyapproachedsignif-
icance.
A consortium of investigators from five institutions in
three European countries, the U.K., The Netherlands, and
Switzerland, determined the incident risk for cancer in re-
lationshiptoexcessBMIamongindividualsin30European
countries [12]. The population attributable risk for cancer
incidence in 2002 for a BMI 25 kg/m
2 was 2.5% (CI,
1.5%–3.6%) for men and 4.1% (CI, 2.3%–5.9%) for
women. This represented an excess of 70,288 (CI, 40,069–
100,668) cases of cancer. When a scenario analysis of a
contemporary population for the year 2008 was done, the
population attributable risk for the incidence of cancer was
3.2% (CI, 2.1%–4.3%) for men and 8.6% (CI,
5.6%–11.5%) for women. This finding suggests a substan-
tiallygreaternumberofcasesofcancerattributabletoover-
weight or obesity in 2008 than in 2002. The risk ratios for
menweresignificantlyhigherforleukemia(1.08;CI,1.00–
1.58),non-Hodgkin’slymphoma(1.06;CI,1.03–1.09),and
myeloma (1.09; CI, 1.01–1.17). For women, the risk ratios
werealsosignificantlyhigherforleukemia(1.13;CI,1.00–
1.30), non-Hodgkin’s lymphoma (1.10; CI, 1.00–1.24) and
myeloma (1.11; CI, 1.07–1.15). The incident burden of the
three major hematological malignancies in 2002 in these
countries, as a result of overweight or obesity for men and
women, was calculated to be 6,915 cases.
A cohort of 43,965 obese people was studied based on
their discharge registrations from Danish hospitals, and the
incidenceofcancerinthoseindividualswascomparedwith
thatoftheDanishpopulation[13].Anelevatedriskforsev-
eral sites of cancer, established to be greater in obese peo-
ple, was found (e.g., esophagus, liver, uterus, kidney). An
elevated risk for leukemia (aggregated) in men and women
combined(RR,1.3;CI,1.0–1.7)wasobserved.Theriskfor
non-Hodgkin’s lymphoma was not significantly elevated
(RR, 1.1; CI, 0.8–1.5). Myeloma risk was not reported.
A study by members of the Division of Epidemiology,
Norwegian Institute of Public Health, explored this associ-
ation for lymphohematopoietic diseases in a large Norwe-
gian cohort [14]. Height and weight were measured in
2,000,611 Norwegian men and women aged 20–74 years
during 1963–2001. Cox proportional hazards regression
models with time since measurement of BMI as the time
variable were used. During follow-up, 24,500 cases of a
lymphohematopoietic malignancy, including lymphomas
of all types, leukemia and myeloproliferative neoplasms of
all types, and myeloma and plasmacytoma, were found.
TheRRfordiseasewasestimatedbyCoxproportionalhaz-
ards regression. The risk for these malignancies in the ag-
gregate increased moderately with increasing BMI in both
sexes. The RR for lymphohematopoietic malignancies (ag-
gregate of lymphoma, leukemia, and myeloma) per five-
unit increase in BMI was 1.11 (CI, 1.08–1.14) in men and
1.08 (CI, 1.05–1.11) in women. Separate analyses for lym-
phoproliferative and myeloproliferative malignancies
showedasignificanttrendforriskwhenmenwereanalyzed
based on groups of increasing BMI—18.5 kg/m
2, 18.5–
24.9 kg/m
2, 25–29.9 kg/m
2, and 30 kg/m
2. The RR in-
creased from approximately 0.83 to 1.24 over the four
(increasing) BMI groups in men. In women, the BMI
groups were broader—18.5 kg/m
2, 18.5–24.9 kg/m
2, 25–
29.9 kg/m
2, 30–34.9 kg/m
2, 35–35.9 kg/m
2, and 40.0 kg/
m
2. Analyses of lymphoproliferative and myeloproliferative
malignancies, individually, showed a significant test for trend
of RR from approximately 0.97 to 1.48 over the six BMI
groups.
STUDIES OF THE RELATIONSHIP BETWEEN
OVERWEIGHT AND OBESITY AND THE FOUR MAJOR
TYPES OF LEUKEMIA
The general studies of cancer risk in the overweight and
obese cited in the preceding section, with a few exceptions,
have not examined the risk for developing the four major
leukemia types: acute myelogenous and lymphocytic leu-
kemia and chronic myelogenous and lymphocytic leuke-
mia.
Epidemiologistswhodonotstudyleukemiaspecifically
sometimes disregard the biological differences among the
myelogenous and lymphocytic leukemia types and sub-
types.Inonestudyofmaleveterans,theincidencesofacute
myelogenous leukemia and chronic lymphocytic leukemia
were significantly greater in male white and black veterans
diagnosed as obese [6]. The numbers of cases for the other
two major categories of leukemia were not presented, pre-
sumably because of relatively small numbers of cases.
A nationwide cohort study of 336,381 people was con-
ducted in Sweden, in which the cohort had a mean age of
34.3yearsandanagerangeof14–82years[15].Duringthe
follow-up period, 372 cases of leukemia (acute lympho-
cytic leukemia, n  47; acute myelogenous leukemia, n 
224; chronic myelogenous leukemia, n  101) and 520
people with myeloma were diagnosed. Chronic lympho-
cytic leukemia was not studied. BMI in study subjects had
no association with the risk for the types of leukemia stud-
ied or myeloma.
A prospective study was conducted of 40,909 Austra-
lians in the Melbourne Collaborative Cohort Study re-
cruited in 1990–1994 and followed for an average of 8.4
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ardregressionmodelswithageasthetimeaxiswereusedto
estimatehazardratios(HRs).Therisk,asjudgedbytheHR,
for myeloid leukemia (acute and chronic) was significantly
associated with BMI in overweight (HR, 5.3; CI, 1.9–15.2)
and obese (HR, 5.0; CI, 1.6–15.2) people, compared with
individualswhohadanormalBMI(25kg/m
2).HRswere
higher for the risk for chronic myelogenous leukemia than
for the risk for acute myelogenous leukemia, but case num-
bers were too small to test homogeneity between the two
myeloid leukemias. No association was found with lym-
phoproliferative diseases.
Inanattempttoexaminetheissueoftheriskforthefour
majorleukemiatypesandobesity,facultyattheDivisionof
NutritionalEpidemiologyconductedameta-analysisofco-
hort studies on the association between excess body weight
and the incidence of leukemia (aggregated) and the four
major subtypes [17]. The studies were published between
1966 and July 2007. A random-effects model was used to
combine the results from individual studies. Nine cohort
studies were found with data on BMI or obesity in relation
to the incidence of leukemia. Compared with individuals
who were not overweight (BMI 25 kg/m
2), the RR for
leukemia (aggregate) was 1.14 (CI, 1.03–1.25) for over-
weight individuals (BMI, 25.0–29.9 kg/m
2) and 1.39 (CI,
1.25–1.54) for obese individuals (BMI 30 kg/m
2). On a
continuous scale, a 5-kg/m
2 greater BMI was associated
with a 13% higher risk for leukemia (RR, 1.13; CI, 1.07–
1.19). In a meta-analysis of two to four cohort studies con-
taining four to six separate populations (e.g., men or
women, white or black men) reporting results on subtypes
of leukemia, the RR associated with obesity (BMI 30 kg/
m
2) was significantly greater for acute lymphocytic leuke-
mia (RR, 1.65; CI, 1.16–2.35), for acute myelogenous
leukemia (RR, 1.52; CI, 1.19–1.95), for chronic myeloid
leukemia (RR, 1.26; CI, 1.09–1.46), and for chronic lym-
phocytic leukemia (RR, 1.25; CI, 1.11–1.41).
Investigators in the Department of Social and Preven-
tive Medicine, University of Laval, Québec, Canada, ana-
lyzed data obtained from a population-based, case–control
study conducted in eight Canadian provinces in 1994–
1997, using the Canadian National Enhanced Cancer Sur-
veillance System [18]. Risk estimates were generated by
applying multivariate logistic regression methods to 1,068
incident leukemia cases confirmed as to histological type
and 5,039 controls, aged 20–74 years. They found a statis-
ticallysignificanthigherriskamongsubjectswiththehigh-
est BMI (30 kg/m
2) for acute myelogenous leukemia
(OR, 1.6; CI, 1.2–2.2), for chronic myelogenous leukemia
(OR, 2.3; CI, 1.5–3.4), and for chronic lymphocytic leuke-
mia (OR, 1.4; CI, 1.0–1.8), with a significant relationship
between increasing BMI and RR (dose–response rela-
tionship). An elevated risk for AML associated with ac-
tive smoking disappeared among obese subjects (BMI
30 kg/m
2).
TheIowaWomen’sHealthStudywasusedtodetermine
whether a high BMI was associated with leukemia devel-
opment [19]. Over 40,000 Iowa women (age, 55–69 years)
completedaself-administeredlifestyleandhealthquestion-
naire in 1986 that included their height and weight. One
hundred ninety-four cases of leukemia during the period
1986–2001, including 72 cases of acute myelogenous leu-
kemia and 84 cases of chronic lymphocytic leukemia, were
used in the analysis. The risk for leukemia (aggregate) in-
creased in relationship to increasing BMI, but that relation-
ship seemed to be the result of a strong relationship for
acute myelogenous leukemia. The risk for acute myeloge-
nous leukemia was greater for women who reported being
overweight(BMI,25.0–29.9kg/m
2)(RR,1.9;CI,1.0–3.4)
or obese (BMI 30 kg/m
2) (RR, 2.4; CI, 1.3–4.5; ptrend 
.006) than for women with a normal BMI (18.5–29.9 kg/
m
2). There was no significant positive association between
BMI and chronic lymphocytic leukemia (ptrend  .6). The
authors estimated that, given the prevalence of overweight
and obesity in the U.S., the population attributable risk for
acutemyelogenousleukemiaasaresultofobesitycouldap-
proach 30% based on these data.
Obesity and Acute Promyelocytic Leukemia
In most studies of the risk for acute myelogenous leukemia
in overweight and obese people, the analyses have not ex-
amined the major subphenotypes of the disease. In a study
of 1,245 newly diagnosed cases of acute myelogenous leu-
kemia at M. D. Anderson Cancer Center in 1980–1995, of
which 120 (9.6%) were cases of acute promyelocytic leu-
kemia, a significant association between elevated BMI and
the risk for acquiring acute promyelocytic leukemia was
observed [20]. Five of the 120 patients with acute promy-
elocytic leukemia had a BMI 50 kg/m
2, whereas none of
theothercasesofacutemyelogenousleukemiadid.Exclud-
ing these massively obese patients did not alter the conclu-
sion that the patients with acute promyelocytic leukemia
hadasignificantlyhigherBMIthanpatientswithothersub-
types of acute myelogenous leukemia.
TherelationshipbetweenBMIandacutepromyelocytic
leukemia was supported by a study of acute myelogenous
leukemia in 29 hospitals in the Shanghai district of China.
The study population included 722 cases of acute myelog-
enous leukemia and 1,444 gender- and age-matched com-
parison patients at the same hospitals [21]. There were 124
cases of acute promyelocytic leukemia among the cases of
acute myelogenous leukemia. Risk estimates (ORs) were
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of acute myelogenous leukemia was inversely related to
BMI. However, there was a significant positive trend for a
relationship between the OR of acute promyelocytic leuke-
mia and increasing BMI. In addition, the OR for acute pro-
myelocytic leukemia in obese subjects (BMI 28 kg/m
2)
was 2.15. (Note that the Working Group on Obesity in
China uses a population value for normal, overweight, and
obese that is approximately 2 kg/m
2 less than in the U.S.
and western Europe.) Acute promyelocytic leukemia was
the only subtype of acute myelogenous leukemia for which
the OR significantly increased in association with increas-
ing BMI.
An elevated BMI may also increase the occurrence of
the differentiation syndrome in patients with acute promy-
elocytic leukemia treated with all-trans retinoic acid (treti-
noin) [22]. Among 39 acute promyelocytic leukemia
patients treated with all-trans retinoic acid and idarubicin,
33 patients had a complete remission. Eleven of the 36 pa-
tients developed the differentiation syndrome within a me-
dian of 12 days (range, 3–23 days) of administration of all-
trans retinoic acid. Six of the nine (66.6%) patients with a
BMI 30 kg/m
2 developed the syndrome, whereas only
fiveofthe27(18.5%)patientswithaBMI30kg/m
2(p
0.01) developed the syndrome. On multivariate analysis,
BMI 30 kg/m
2 remained an independent predictor of the
differentiationsyndromeinadditiontobaselinetotalleuko-
cyte count.
A biological link between obesity and acute promyelo-
cytic leukemia was provided by studies on the effect of lep-
tin on these cells [23]. The primary role of leptin, encoded
by the OB gene, is to control fat tissue mass. Leptin is prin-
cipally secreted from fat cells and its serum levels are
highly positively correlated with body fat volume [24]. Its
regulation and role in regulation of the body mass of fat
cells is, however, more complicated than a straightforward
physiological setpoint relationship [24]. Leptin acts on the
hypothalamus to decrease appetite, among other effects.
The leptin receptor gene (OB-R) is a homologue of the in-
terleukin (IL)-6–type, cytokine receptor gene. Leptin and
its receptor play a role in hematopoiesis [25]. Leptin recep-
tors are expressed on marrow mononuclear cells and the
CD34
 cell population, specifically. Leptin acts synergis-
tically with stem cell factor to stimulate the growth of gran-
ulocyte-monocyte progenitors in human marrow. That
progenitor cell is thought to be the site of transformation of
cases of acute promyelocytic leukemia. The long isoform
variant of the leptin receptor is present on the
CD34
CD33
 fraction of marrow cells from patients with
acute promyelocytic leukemia but is not present on normal
promyelocytes [23]. These findings have led to the postu-
lationthattheproliferationofleukemicpromyelocytesmay
bedriveninpartbyleptinlevels,giventhatitsreceptorison
leukemic but not normal promyelocytes. In addition, leptin
inhibits the programmed cell death of leukemic cells. Thus,
its action on leukemic promyelocytes is to foster prolifera-
tion and inhibit cell death, the two major signals for pro-
moting leukemia growth. These effects should be
accentuatedinoverweightandobese.Leptinreceptorswere
also found on the cells of a majority of cases of acute my-
elogenous leukemia, regardless of phenotypic subtype.
Obesity and Chronic Myelogenous Leukemia
Ineightstudiesoftherelationofobesitytochronicmyelog-
enous leukemia, a significant association was found in six
[11, 14, 16–18, 26], but not in two others [6, 15]. A case–
control study (n  253 cases and n  270 controls), con-
ducted at the University of Texas M. D. Anderson Cancer
Center investigated the role of BMI and weight gain during
adulthood in the risk for chronic myelogenous leukemia,
using multivariate logistic regression for analysis [26].
Cases were more likely to be obese during adulthood than
controlsatage25(OR,4.29;CI,1.63–11.3),atage40(OR,
5.12; CI, 1.92–13.6), and at diagnosis (OR, 3.09; CI, 1.56–
6.13). Obesity at all ages was found to be an independent
risk factor for chronic myelogenous leukemia, with a sig-
nificant dose–response effect. The OR increased strikingly
from overweight to mildly obese to severely obese. Among
participants 45 years old, patients gained significantly
more weight each year during the ages of 25–40 than con-
trols (0.78 versus 0.44 kg/year; p  .001), and the associa-
tion with chronic myelogenous leukemia was strongest
among those who gained 1 kg/year during the ages of
25–40years(OR,3.63;CI,1.46–9.04).Theseinvestigators
concluded that obesity and weight gain during adulthood
play important roles in the risk for the onset of chronic my-
elogenous leukemia.
The Relationship Between Obesity and the Risk
for Lymphoma
Hodgkin’s Lymphoma
Investigators in the Epidemiology and Genetics Unit, Uni-
versity of York, U.K., studied the relationship between
Hodgkin’s lymphoma and obesity in a population-based
case–control study that recruited incident cases of lym-
phoma in England during 1998–2003 [27]. Information on
height and weight was collected from 216 cases with a
pathologically confirmed diagnosis of Hodgkin’s lym-
phoma and their age- and sex-matched controls. Obesity
was defined as BMI 30 kg/m
2 5 years prior to diagnosis.
This weight status led to a higher risk for Hodgkin’s lym-
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normal BMI range (18.5–24.9 kg/m
2). The OR for the risk
for Hodgkin’s lymphoma was 2.2 (CI, 1.1–4.3). The asso-
ciation was significant among men (OR, 2.8; CI, 1.2–6.5)
but not among women (OR, 1.1; CI, 0.3–3.8). Elevated risk
tended to be among older (aged 35 years) rather than
younger(aged35years)individuals,andforEpsteinBarr
virus–negativeratherthanpositivecases.Anotherstudydid
not find a significantly greater risk for Hodgkin’s lym-
phoma in white or black male military veterans related to
BMI [6]. The calculated RRs were elevated modestly but
the confidence limits extended below 1.0.
A very early study on the relationship of obesity to can-
cer, in 1978, using the medical records of 50,000 alumni of
Harvard University and the University of Pennsylvania,
found an association between a high ponderal index
(weight/height [3]), a precursor of BMI, and the risk for
Hodgkin’s lymphoma [28]. That study, however, suffered
from the use of histological diagnoses based on the 1957
ICD codes and the rudimentary experimental design and
statisticalmethodsofthedaytodealwithmultivariateanal-
ysis.
Non-Hodgkin’s Lymphoma
Staff at the Surveillance and Risk Assessment Division,
Centre for Chronic Disease Prevention and Control, Public
Health Agency of Canada, conducted a population-based
case–control study of 1,030 cases of histologically con-
firmed non-Hodgkin’s lymphoma and 3,106 controls to as-
sess the impact of recreational physical activity, obesity,
and energy intake on non-Hodgkin’s lymphoma risk in
Canada in 1994–1997 [29]. The study was part of the Ca-
nadian National Enhanced Cancer Surveillance System.
Those investigators used unconditional logistic regression
and distributed BMI into quartiles, based on its distribution
in the control population. They also examined the relation-
ship between obesity and subtypes of lymphoma. Obesity
(BMI 30 kg/m
2) was associated with a ORs for non-
Hodgkin’s lymphoma of 1.59 (CI, 1.18–2.12) for men and
1.36 (CI 1.00–1.84) for women. For men and women with
a lifetime maximum BMI 30 kg/m
2, the respective ORs
were 1.55 (CI 1.16–2.06) and 1.10 (CI 0.83–1.46). The OR
increased with each quartile of increasing BMI in both men
(OR, 0.58, 1.00, 1.29, and 1.58) and women (OR, 0.68,
1.00, 1.16, and 1.36) after multivariable adjustment. This
trend in ORs was highly significant among men (p  .001)
but not quite significant for women (p  .068). Some dif-
ferences were found among histologic subtypes of non-
Hodgkin’slymphomafortheassociationwithobesity.This
study also indicated that recreational physical activity de-
creased non-Hodgkin’s lymphoma risk, whereas obesity
and excess calorie intake increased the risk. Cases were
stratified by diffuse lymphoma (40.7% of total cases), fol-
licular lymphoma (23.5%), small lymphocytic lymphoma
(9.7%), and all other types of lymphoma (26.1%). The re-
lationship with obesity was stronger in the diffuse lym-
phoma and all other types of lymphoma groups, but low
case numbers after four-way stratification may have influ-
enced this outcome.
In a collaboration between epidemiologists at the Karo-
linska Institute, Stockholm, and the U.S. National Cancer
Institute, a population-based Swedish cohort of patients
with a discharge diagnosis of obesity in 1965–1993 was
studiedandtheirincidenceofcancerwasobtainedfromthe
Swedish Cancer Registry [30]. The standardized incidence
ratio (SIR) was used to assess cancer risk. Overall, a 33%
excess cancer incidence was found. Among these was a
higherincidenceoflymphomas(SIR,1.4;CI,1.0–1.7).The
risk for Hodgkin’s lymphoma was elevated in men (SIR,
3.3;CI,1.4–6.5)andtheriskfornon-Hodgkin’slymphoma
was elevated in women (SIR, 1.6; CI, 1.2–2.1).
Investigators from five academic centers and the Na-
tional Cancer Institute evaluated the role of obesity (and
other variables) in a population-based, case–control study
conducted in Detroit, Iowa, Los Angeles, and Seattle in
1998–2000 [31]. HIV
 cases of non-Hodgkin’s lym-
phoma, aged 20–74 years, were reported in each area (n 
1,321). Controls were identified through random digit dial-
ingandMedicarefiles,andwerematchedtocasesbasedon
sex, age, race, and study site (n  1,057). Risk factor data
were collected by in-person interviews and self-adminis-
tered questionnaires. Unconditional logistic regression was
used to estimate the OR, adjusted for age, sex, race, and
study center. High BMI (35 kg/m
2), compared with nor-
mal body size (25 kg/m
2), was positively associated with
the risk for diffuse non-Hodgkin’s lymphoma (OR, 1.73;
CI, 1.15–2.59) but was not associated with the risk for fol-
licular lymphoma or all non-Hodgkin’s lymphomas com-
bined. In a multivariate model to predict the risk for diffuse
non-Hodgkin’s lymphoma in patients with a high BMI
(35 kg/m
2), compared with a normal BMI (25 kg/m
2),
theORwas2.15(CI,1.09–4.25).BMIwasassociatedwith
the risk for this lymphoma subtype.
Members of the Department of Preventive Medicine,
Feinberg School of Medicine, Northwestern University,
evaluated the association of non-Hodgkin’s lymphoma
with BMI and postload plasma glucose level, which is pos-
itively associated with BMI. They analyzed data from a co-
hort study to investigate associations of interviewer-
measured BMI and postload plasma glucose with risk for
non-Hodgkin’s lymphoma mortality and to explore associ-
ations with leukemia and myeloma [32]. Employees of 84
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years at baseline, were screened in 1967–1973. Height and
weightweremeasuredbystudynurses.A50-goralglucose
load was administered to nondiabetic participants. Of the
cohort at risk, 35,420 men and women, 129 died of non-
Hodgkin’slymphoma,151diedofleukemia,and66diedof
myeloma during an average of 31 years of follow-up. HRs
and CIs were derived from Cox proportional hazards re-
gression models. Among men, there was a positive dose–
response relationship between BMI and mortality from
non-Hodgkin’s lymphoma (HR, 2.57; CI, 1.24–5.34) for
the highest versus lowest quartile (ptrend  .01). Postload
plasma glucose also was positively related to non-
Hodgkin’s lymphoma mortality (HR, 2.86; CI, 1.35–6.06)
for the highest versus lowest category (ptrend  .004).
Researchers in the Scandinavian Lymphoma Etiology
Studyusedtelephoneinterviewsof3,055patientswithnon-
Hodgkin’s lymphoma and 618 patients with Hodgkin’s
lymphoma diagnosed between October 1, 1999 and August
30, 2002 and 3,187 population-based control subjects [33].
The interviews assessed current height, adult weight, and
other possible risk factors. Multivariable ORs for risk for
lymphomawereestimatedbyunconditionallogisticregres-
sion.Inthistelephonesurvey,BMIwasnotassociatedwith
theriskforoverallnon-Hodgkin’slymphomaortheriskfor
Hodgkin’s lymphoma (e.g., comparing the highly obese
group [BMI 35.0 kg/m
2] with the normal-weight group
[BMI,18.5–24.9kg/m
2].AlthoughBMIwasnotassociated
with the risk for non-Hodgkin’s lymphoma, there was evi-
denceofapositiveassociationwiththeriskfordiffuselarge
B-celllymphoma(OR,1.5;CI,0.9–2.4;ptrend.05),com-
paring the highly obese group with the normal-weight
group.
Two case–control studies of the relationship of BMI to
lymphomaconductedintheprovinceofPordenone,greater
Milan, and Naples, Italy in 1995–2002 included 671 pa-
tients with pathologically confirmed non-Hodgkin’s lym-
phoma,aged17–84years(median,58years),and220cases
of Hodgkin’s lymphoma, aged 14–77 years (median, 37
years) [34]. They were compared with 1,799 control sub-
jects.Trainedinterviewersquestionedpatientsandcontrols
astotheirheightandweight1yearpriortodiagnosis.Using
a multivariate analysis of quintiles of BMI, they found no
significant risk (OR) for non-Hodgkin’s lymphoma or
Hodgkin’s lymphoma in any quintile of BMI when com-
pared with the lowest BMI category (22.3 kg/m
2). They
also looked at normal, overweight, and obese categories of
BMI as defined by the World Health Organization and
found no significant association of BMI with lymphoma.
WhenBMIatage30andage50yearswasconsidered,there
wasnoassociationofBMIwiththeriskforlymphoma[35].
Faculty at Northwestern University and the University
ofNebraskaexaminedtheassociationbetweenBMIandthe
risk for non-Hodgkin’s lymphoma according to histologic
subtypes and the BMI at different periods in a person’s life.
This population-based, case–control study of 387 patients
withnon-Hodgkin’slymphomaand535controlsconducted
in Nebraska in 1999–2002 recovered data on adult weight
atage20–29,40–49,and60–69years,height,physicalac-
tivity, and other lifestyle factors by telephone interview
[36]. Risk was estimated by the OR, adjusting for age, total
energyintake,physicalactivity,andotherconfoundingfac-
tors. A higher adult BMI was associated with the risk for
non-Hodgkin’s lymphoma (OR, 1.4; CI, 0.9–2.0) when the
obese group (BMI 30.0 kg/m
2) was compared with the
normal-weight group (BMI, 18.5–24.9 kg/m
2). The risk
was higher for those who were class 2 obese (BMI 35.0
kg/m
2)(OR,1.7;CI,1.0–2.9).Thepositiveassociationwas
similar among men and women. An excess risk for non-
Hodgkin’s lymphoma was associated with high BMI at
ages 40–49 years (OR, 1.6; CI, 1.0–2.5), but although risk
was elevated, it was not significant at ages 20–29 years
(OR, 1.4; CI, 0.8–2.5). Obesity at ages 40–49 years was
also associated with a higher risk for small lymphocytic
lymphoma (OR, 4.5; CI, 1.5–13.3), diffuse large B-cell
lymphoma(OR,1.8;CI,0.9–3.9),andfollicularlymphoma
(OR, 1.8; CI, 0.9–3.5).
Researchers at the School of Public Health, University
of California, Berkeley, reviewed epidemiologic reports
thathavestudiedtherelationshipbetweenobesity,physical
activity,anddietandtheriskfornon-Hodgkin’slymphoma
based on published case–control and prospective cohort
studies. In 2005, they concluded that overweight and obe-
sity probably increases the risk for non-Hodgkin’s lym-
phoma, whereas moderate physical activity may reduce the
risk [37].
Investigators at the Cancer Research Center in Hono-
lulu, Hawaii explored the relation of non-Hodgkin’s lym-
phoma to body size at different times in life within a
multiethnic cohort that includes Americans of African an-
cestry, of European ancestry, of Japanese ancestry, of His-
panicancestry,andNativeHawaiiansfromHawaiiandLos
Angeles County. Participants were 45 to 75 years old at re-
cruitment in 1993 to 1996. This analysis included 87,079
men and 105,972 women among whom there were 461
male and 378 female cases of non-Hodgkin’s lymphoma
[38]. Cox regression was used to model non-Hodgkin’s
lymphoma risk with age as the time metric, adjusting for
ageatentryintothecohort,ethnicity,education,alcoholin-
take,andageatfirstlivebirth.BodyweightandBMIatage
21 were stronger predictors of non-Hodgkin’s lymphoma
riskthananthropometriccharacteristicsatentryintotheco-
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age 21 had a nonsignificant 86% and 41% higher risk for
non-Hodgkin’slymphoma,respectively,whereastherewas
no association with their BMI at entry into the cohort. For
women, the risk associated with the highest quartile of
weight at age 21 was 1.6, Ptrend  0.04, whereas women in
the highest quartile of BMI at entry into the cohort had a
nonsignificant risk of 27%. Despite the small numbers,
there was some consistency for risk estimates across ethnic
groups and weak evidence for an association with non-
Hodgkin’slymphomamajorsubtypes.Theyconcludedthat
weight at age 21 may represent lifetime effects of adiposity
better than body weight at cohort entry. Weight at age 21
may be more relevant for the estimating risk for non-
Hodgkin’s lymphoma.
Investigators at eight academic institutions and the Na-
tional Cancer Institute compared the risk for lymphoma
subtype for several putative risk factors in a population-
based case–control study, including diffuse large B-cell
lymphoma(n416),follicularlymphoma(n318),mar-
ginal zone lymphoma (n  106), and chronic lymphocytic
leukemia/small lymphocytic lymphoma (n  133) [39].
Theyrequiredatleasttwoofthreeanalyses(polytomouslo-
gistic regression, homogeneity tests, or dichotomous logis-
tic regression) to support differences in risk related to an
anthropometric factor, such as BMI. Very high BMI (35
kg/m
2) was associated with a higher risk for diffuse large
B-cell lymphoma (OR, 1.7; CI, 1.1–2.5) but not follicular,
marginal zone, or small lymphocytic lymphoma.
To investigate whether long-term over- or under-nutri-
tion is associated with non-Hodgkin’s lymphoma, self-
reported anthropometric data on weight and height from
10,000 cases of non-Hodgkin’s lymphoma and 16,000
controls were pooled across 18 case–control studies iden-
tified through the International Lymphoma Epidemiology
Consortium [40]. Study-specific ORs were estimated using
logistic regression and combined using a random-effects
model. Severe obesity, defined as a BMI 40 kg/m
2, was
not associated with non-Hodgkin’s lymphoma overall
(pooled OR, 1.00; CI, 0.70–1.41) or the majority of non-
Hodgkin’s lymphoma subtypes examined. An excess risk
was observed for diffuse large B-cell lymphoma (pooled
OR, 1.80; CI, 1.24–2.62), although not all study-specific
ORs were raised. Among the overweight (BMI, 25–29.9
kg/m
2) and obese (BMI, 30–39.9 kg/m
2), risk was elevated
in some studies and not in others, whereas no association
was observed among the underweight (BMI 18.5 kg/m
2).
There was little indication of an increasing OR for non-
Hodgkin’s lymphoma or its subtypes with every 5-kg/m
2
rise in BMI above 18.5 kg/m
2.
Members of the Department of Epidemiology, GROW-
School for Oncology and Developmental Biology, Maas-
tricht University, Maastricht, The Netherlands, examined
the association between BMI and the risk for lymphocytic
malignancies in the Netherlands Cohort Study [41]. The
participants, 120,852 Dutch men and women aged 55–69
years, completed a self-administered questionnaire at entry
into the cohort in 1986. After 13.3 years of follow-up, data
on 1,042 lymphatic malignancy cases (including diffuse
large-cell lymphoma, follicular lymphoma, chronic lym-
phocytic leukemia, myeloma, and macroglobulinemia) and
4,588subcohortmemberswereavailable.Incidenceratera-
tios were estimated using Cox regression models. BMI at
baselineandBMIchangesincetheageof20yearswerenot
associated with the risk for a lymphocytic malignancy.
However,therateratiooflymphaticmalignanciesperfour-
unit increase in BMI at 20 years of age was 1.13 (CI, 1.01–
1.25). BMI at 20 years of age and at entry into the study
were self-reported by participants through a questionnaire.
Researchers in the Epidemiology and Genetics Unit,
University of York, U.K., in a population-based case–con-
trol study of lymphomas in England collected height and
weight details from 699 non-Hodgkin’s lymphoma cases
and 914 controls [42]. Obesity, defined as a BMI 30
kg/m
2 5 years before diagnosis, was associated with an el-
evatedriskfornon-Hodgkin’slymphoma(OR,1.5;CI1.1–
2.1).Theexcessriskwasmostpronouncedfordiffuselarge
B-cell lymphoma (OR, 1.9; CI 1.3–2.8).
Investigators in the Division of Nutritional Epidemiol-
ogy, the National Institute of Environmental Medicine,
KarolinskaInstitute,Stockholm,conductedameta-analysis
to summarize the epidemiologic evidence on the associa-
tion between excess body weight and the risk for non-
Hodgkin’s lymphoma [43]. Relevant studies were
identifiedbysearchingMEDLINE(1966toFebruary2007)
and the reference lists of retrieved publications. They in-
cluded cohort and case–control studies that reported RR
estimates for the association between BMI and non-
Hodgkin’s lymphoma incidence or mortality. A random-
effects model was used to combine results from individual
studies. Sixteen studies (10 cohorts and six case–control
studies),with21,720cases,mettheinclusioncriteria.Com-
pared with individuals of normal weight (BMI 25.0 kg/
m
2), the summary RR for non-Hodgkin’s lymphoma was
1.07 (CI, 1.01–1.14) for overweight individuals (BMI, 25–
29.9 kg/m
2) and 1.20 (CI, 1.07–1.34) for those who were
obese (BMI 30.0 kg/m
2). A meta-analysis stratified by
histologic subtypes showed that obesity was associated
with a statistically significant greater risk for diffuse large
B-cell lymphoma (RR, 1.40; CI, 1.18–1.66; n  6 studies)
but not follicular lymphoma (RR, 1.10; CI, 0.82–1.47; n 
6 studies) or small lymphocytic lymphoma/chronic lym-
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They concluded that excess body weight is associated with
an elevated risk for non-Hodgkin’s lymphoma, especially
diffuse large B-cell lymphoma.
Investigators used the Prostate, Lung, Colorectal, and
OvarianCancerScreeningTrialtoevaluatetheriskfornon-
Hodgkin’s lymphoma and its subtypes in association with
anthropometric factors, smoking, and alcohol consumption
in a prospective cohort study. Lifestyle was assessed by a
questionnaire completed by 142,982 male and female par-
ticipants, aged 55–74 years, enrolled in the screening trial
during 1993–2001 [44]. HRs were calculated using Cox
proportional hazards regression. During 1,201,074 person-
years of follow-up through 2006, 1,264 confirmed cases of
non-Hodgkin’s lymphoma and 243 cases of myeloma were
identified. Higher BMI at ages 20 and 50 years and at en-
rollment (entry) was associated with a greater risk for non-
Hodgkin’s lymphoma (ptrend  .01 for all; e.g., at entry,
BMI 30 versus 18.5–24.9 kg/m
2; HR, 1.32; CI, 1.13–
1.54) and for myeloma (ptrend  .01 to  .001 for all; at en-
try, BMI 30 versus 18.5–24.9 kg/m
2; HR, 1.69; CI 1.18–
2.41).
Obesity and the Risk for Myeloma
Staff at the Division of Research, Kaiser Permanente Med-
ical Care Program, in Oakland, California, conducted a
study of common clinical conditions as predictors of sub-
sequent cancer in 143,574 outpatients of their health main-
tenance organization [45]. An association was noted
betweenobesity,diagnosedin14,388patients,andthesub-
sequent development of myeloma up to 21 years (33 cases
observed, 21.3 expected based on the experience of the en-
tire cohort; standardized morbidity ratio, 1.55; CI, 1.06–
2.17). This association was evaluated further in a second
cohort of 163,561 multiphasic-checkup examinees fol-
lowedupforasmanyas24years.BMIatentryexamination
was associated positively with the incidence of myeloma in
whitemen(e.g.,RR,1.07;CI,1.01–1.15perunitincreasein
BMI; RR, 1.68; CI, 0.75–3.78 comparing the highest with
the lowest quartile). This association was absent in white
women,partiallyconfirmedinblackmenandwomen(BMI
quartiles two, three, and four showed a higher risk than
quartile one), and not explained by the presence of diabetes
mellitus.TheassociationwithBMIwaslessorabsentbased
on reported greatest adult weight, and in white women was
inverse with BMI based on reported lowest adult weight.
Among subjects with more than one checkup, greater risk
was associated directly with weight loss among white men
and associated inversely with weight gain among black
women. These investigators concluded that body build or
nutritional status may be involved in the development of
myeloma.
AstudyofBMIandtheriskformyelomawasconducted
in 109,698 men and women in Japan, aged 40–79 years
[46]. A Cox proportional hazard model was used to calcu-
late the age- and sex-adjusted HR for myeloma. The ratio
for men was significantly higher than for women (HR, 1.5;
CI, 1.0–2.2). For men and women, a BMI 30 kg/m
2 was
associated with a significantly greater age- and sex-ad-
justed risk for myeloma (HR, 2.8; CI, 1.0–7.7).
Investigators from the Michigan Cancer Foundation in
Detroit, the New Jersey Department of Health, Emory Uni-
versity, and the National Cancer Institute collaborated to
explore the association of BMI with the risk for myeloma
(OR) among black men and women compared with white
men and women, age 30–79 years, in the U.S. in patients
diagnosed in 1986–1989 [47]. The 345 white men and
womenand191blackmenandwomenwithmyelomawere
comparedwith1,082whiteand899blackcontrolswhopar-
ticipated in a population-based, case–control study of my-
eloma in three areas of the U.S. (Michigan, Georgia, and
New Jersey). The World Health Organization categories of
underweight, normal, overweight, and obese, based on
BMI, were used to categorize study subjects. Data were an-
alyzed by unconditional logistic regression. An elevated
risk for myeloma was associated with obesity (BMI 30
kg/m
2) as compared with normal weight (BMI, 18.5–24.9
kg/m
2)—OR, 1.9 (CI, 1.2–3.1) for white men and women
and OR, 1.5 (CI, 0.9–2.4) for blacks. A significant trend in
risk was present for white men and women and black
women (but not black men) from normal to overweight to
obese subjects. The frequency of obesity was greater for
black than for white controls.
Investigators at the Mayo Clinic and University of Min-
nesota examined the association between anthropometric
characteristics and the incidence of myeloma in a prospec-
tive, population-based sample of 37,083 postmenopausal
women. In 1986, the women completed a mailed question-
naire that included self-report of height and weight and
measurement of waist and hip circumferences [48]. During
16 years of follow-up, 95 cases of myeloma were identified
through linkage to the Iowa Cancer Registry. In an age-
adjusted model, women in the highest category of several
anthropometric measurements, compared with the lowest
category, had a higher risk for developing myeloma. For
BMI (kg/m
2), the rate ratio was 1.5 (CI, 0.92–2.6); for
weight it was 1.9 (CI, 1.1–3.4), for waist circumference it
was 2.0 (CI, 1.1–3.5), and for hip circumference it was 1.8
(CI, 1.0–3.0).
Researchers in the Department of Preventive Medicine,
Keck School of Medicine, University of Southern Califor-
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tional Cancer Institute evaluated IL-6 genotypes and BMI
in a case–control study of myeloma and plasmacytoma
[49]. DNA samples and questionnaires were obtained from
134 cases of myeloma and 16 cases of plasmacytoma from
the Los Angeles County population-based cancer registry
and from 112 siblings or cousins of cases (family controls)
and126populationcontrols.Genotypesevaluatedincluded
theIL-6promotergenesinglenucleotidepolymorphismsat
positions 174, 572, and 597; one variable number of
tandemrepeats(373A(n)T(n));andonesinglenucleotide
polymorphism in the IL-6 receptor  gene at position
358. The variant allele of the IL-6 promoter single nucle-
otide polymorphism 572 was associated with an approx-
imately twofold greater risk for myeloma when cases were
compared with family (OR, 1.8; CI, 0.7–4.7) or population
controls (OR, 2.4; CI, 1.2–4.7). Obesity (BMI 30 kg/m
2)
was associated with a nonsignificant 40% and 80% higher
risk when myeloma cases were compared with family con-
trols or population controls, respectively, relative to per-
sons with a BMI of 25 kg/m
2. Increasing BMI was not
significantly associated with an elevated risk for myeloma
when cases were compared with the population control
(ptrend  .08).
In a study of the relationship between BMI and my-
eloma incidence at the Harvard Medical School, Harvard
School of Public Health, and Jerome Lipper Multiple My-
eloma Center at the Dana-Farber Cancer Institute, 136,623
individuals were followed (2.1 million person-years at
risk) and 215 incident cases of myeloma occurred [50].
BMI was positively and significantly associated with my-
elomaincidence.Theassociationwasstrongestinmenwith
aB M I30 kg/m
2, when compared with those with a BMI
22 kg/m
2, resulting in an RR two and one half times that
ofleanindividuals(RR,2.4;CI,1.0–6.0).TheRRwassig-
nificantly elevated (RR, 1.6; CI, 1.0–2.7) for women in the
overweight category (BMI, 25–29.9 kg/m
2), but not in
obese women (BMI 30 kg/m
2) (RR, 1.2; CI, 0.7–2.2).
Epidemiologists at the Karolinsksa Institute, Stock-
holm, conducted a meta-analysis to quantitatively summa-
rize the evidence from epidemiologic studies of the
association of overweight and obesity with the risk for
multiple myeloma. They searched the MEDLINE and
EMBASE databases (1966 to May 2007) and the reference
lists of retrieved articles. Cohort and case–control studies
were included if they reported RR estimates for the relation
between BMI and myeloma incidence or mortality. A ran-
dom-effects model was used to combine study-specific re-
sults. In total, 11 cohort studies (involving 13,120 cases)
and four case–control studies (1,166 cases and 8,247 con-
trols) were included in the meta-analysis [51]. Compared
with individuals of normal weight, the risk for myeloma
wasstatisticallysignificantlyhigheramongthosewhowere
overweight (cohort studies: RR, 1.12; CI, 1.07–1.18; case–
control studies: RR, 1.43; CI, 1.23–1.68) or obese (cohort
studies:RR,1.27;CI,1.15–1.41;case–controlstudies:RR,
1.82; CI, 1.47–2.26).
Investigators at the Mayo Clinic and the National Can-
cer Institute screened 1,000 black and 996 white women
(age 40–79 years) of similar socioeconomic status for es-
sential monoclonal gammopathy in order to study the risk
for acquiring essential monoclonal gammopathy in relation
toobesityandethnicity[52].Thirty-nine(3.9%)Americans
of African ancestry and 21 (2.1%) Americans of European
ancestry had essential monoclonal gammopathy. On multi-
variate analysis, obesity (OR, 1.8; p  .04) and African an-
cestry (OR, 1.8; p  .04) were independently associated
with an excess risk for this clonal precursor of myeloma.
DISCUSSION
Leukemia Subtypes
Table 1 summarizes the findings of the studies described in
this paper. Some studies of obesity and leukemia have suf-
fered from the failure to consider, at least, the four major
categories of leukemia. There is a reluctance to stratify ex-
haustivelybecausethesamplesizeperanalyticalcellwould
be insufficient to minimize a type 2 statistical error. Never-
theless, showing the stratified data for subtypes in addition
to the aggregate results in studies of leukemia and lym-
phoma would permit later meta-analyses to consider the
question of subtypes. This problem is highlighted by a
studyindicatingthatasignificantrelationshipbetweenobe-
sity and the risk for acute promyelocytic leukemia exists,
but in that study there was no association with all cases of
acute myelogenous leukemia [21]. The latter subtype rep-
resents about 8%–10% of all cases of acute myelogenous
leukemia in the U.S., although in the study cited it repre-
sented about 17% of cases of acute myelogenous leukemia
in the Shanghai district of China [21]. The putative role of
elevated leptin levels in the higher RR for acute promyelo-
cytic leukemia in obese persons was discussed above.
Considering the diagnostic category “leukemia” has the
dual risk of missing the significance of an association with
one subtype (e.g., acute myelogenous leukemia versus the
other three types), because of the diluting effect of irrele-
vant cases on the one hand, and mistakenly concluding that
all four types of leukemia have elevated risks, as a result of
the strong effect of one or two relevant types, leading to a
significant association with leukemia in the aggregate, on
the other hand. In the findings reviewed in this paper, there
was a significant association between obesity and the risk
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1096 Obesity and Hematological Malignanciesfor leukemia in the aggregate [5–8, 10, 12–14, 17–19, 32],
theriskforacutemyelogenousleukemia[6,14,16–19],the
riskforacutepromyelocyticleukemiaonlyamongtheacute
myelogenous leukemias [20, 21], the risk for chronic my-
elogenous leukemia [11, 14, 16–18, 26], the risk for acute
lymphocytic leukemia [14, 17, 18], and the risk for chronic
lymphocytic leukemia [6, 11, 14, 17, 18].
Lymphoma Subtypes
Themostcarefullyconstructedandlargestpopulationstud-
ies concluded that obesity is a risk factor for lymphoma [5,
7–12, 14, 29, 30, 31, 32, 36–40, 41–44], but most studies
have not examined the major subtypes. A few studies have
notfoundanassociationbetweenobesityandlymphoma[6,
13,16,33,34].Severalstudieshavefoundariskfordiffuse
lymphomas,or,morespecifically,diffuselargeB-celllym-
phoma [31, 33, 36, 39, 40–44]. The association between
obesity and the risk for follicular lymphoma was observed
in three studies [32, 36, 44], but not in others [29, 31, 43].
Because diffuse large B-cell lymphoma makes up about
35%–40% of all cases of lymphoma in western societies, a
strong association between that phenotype and obesity
could account for some of the results studying all lympho-
mas in the aggregate. Although there have been ambiguous
results for the association between obesity and the risk for
follicular lymphoma, these two lymphomas constitute
about 65%–75% of lymphoma cases in western countries
and could result in a significant relationship with obesity
when all lymphomas are aggregated.
Myeloma
The data linking obesity with myeloma may be the most
compelling among the hematological malignancies, based
on replication in a majority of studies [5–8, 10–12, 14, 24,
41–47, 50], but not in several others [9, 15, 16, 32, 41, 49].
The conclusion that a significant relationship exists be-
tween obesity and the risk for myeloma was supported by a
meta-analysis of 11 cohort and four case–control studies
[51]. The relationship between single nucleotide polymor-
phisms of the IL-6 promoter gene and obesity and between
IL-6 and the growth-fostering and cell survival–promoting
effects on myeloma cells is intriguing [49], but a definitive
interrelationship has not been established.
Population Attributable Risk and Prevention
Although we do not have a certain value for the population at-
tributableriskforhematologicalmalignanciesassociatedwith
obesity, even a small increase in risk is consequential because
of the markedly shortened life span in persons with these dis-
eases. The clinical importance of these finding is the possibil-
ity of decreasing the incidence of the hematological
malignancies through prevention. Hematological malignan-
cies in adults have onerous treatment protocols and a low cure
rate[53].Anobstacletoinvokingpreventionistheinadequacy
ofmethodsforbehaviormodificationthatareconsistentwitha
free society wrapped in abundance. The morbidity and mor-
tality from cancer (let alone the cost) could be markedly re-
duced by a decrease in smoking, alcohol abuse, overeating,
and underexercising. In the specific case of acute myeloge-
nous leukemia, the incidence, and thereby the mortality rate,
could be significantly decreased if tobacco smoking [54] was
further curtailed and, apparently, if caloric intake could be re-
duced and exercise increased in relevant populations. In gen-
eral, the prevention of hematological malignancies is not a
focus of hematologists because the risk factors are either not
yet established to a degree of medical certainty or, for those
that are, seem beyond the ability of an individual physician to
modify. Chemical exposure, notably to benzene, has been
dealt with by government workplace regulation, making ben-
zene-inducedacutemyelogenousleukemiaormyelodysplasia
vanishingly rare in developed countries. The association be-
tween acute myelogenous leukemia and tobacco smoking is
being addresses by the American Cancer Society, the U.S.
Public Health Service, state programs, and nongovernmental
agencies through vigorous antismoking campaigns and pro-
gramsofsmokingcessation.Researchthatcouldleadtointer-
ventions that block central nervous system signals that
mediate craving for tobacco or appetite could be useful.
Biological Plausibility
One of the important missing links in the putative relationship
betweenoverweightandobesityandthehematologicalmalig-
nancies is biological plausibility. How does obesity lead to
cancer,ingeneral,andleukemia,lymphoma,andmyeloma,in
particular?Becausethesediseasesrequireaseriesofgenemu-
tations, one could ask: “Are these mutations independent of
obesity?” But the de novo genetic changes are more likely to
lead to clonal dominance because of the metabolic and endo-
crinologic changes induced by obesity. The example given in
acute promyelocytic leukemia links the greater concentration
of leptin resulting from a greater mass of fat to a milieu that
favors growth and impaired programmed cell death of leuke-
mic promyelocytes. This explanation indicates that the trans-
forming events occur at similar frequencies in lean and fat
individuals but the latter have a higher probability of having a
clone emerge. The latter can be thought of as the selection hy-
pothesis.Alternatively,insomeasyetundefinedmanner,obe-
sitymayacceleratethemutationalrateofcellsorinterferewith
cellular mechanisms of DNA repair resulting in mutational
events, increasing the inherent rate of mutation in tissue cells
or influencing the role of epigenetic factors in cell regulation.
This represents an inductive effect. A dietary effect on mi-
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biochemicalnutritioniststhatcouldlinkobesitytocarcinogen-
esis. The relationship between dietary patterns and food
groups and the risk for non-Hodgkin’s lymphoma is reviewed
elsewhere [33].
Ideally,therelationshipbetweenacausalfactorandacan-
cerisestablishedbyatleastone,butpreferablytwo,ofthefol-
lowing approaches: carefully conducted epidemiological
studiesthat,intheaggregate,providecompellingevidencefor
a causal association (e.g., smoking and lung cancer); animal
studiesshowingthatthecausalfactorunderstudycaninducea
reasonablefacsimileofthehumandiseaseinexperimentalan-
imals (e.g., experimental smoke inhalation in animals); and
studies showing that the risk factor under study can cause ge-
netic changes that replicate the causal genetic changes in the
humandisease(e.g.,inductionoftheBCR-ABLoncogenewith
radiationofBCR-ABL
cells).Thelattertworequirementsare
oftennotunachievable,sowerelyheavilyonepidemiological
studies,manyofwhicharelimitedby(a)relativelysmallpop-
ulations, (b) “convenience” sampling, (c) case–control ap-
proaches,makingtheselectionofacomparisongroupcritical,
(d)questionnaires,(e)self-reportedkeyvariables,(f)multivar-
iate complexities, (f) investigator bias, (g) attrition rates from
cohort studies, and (h) other limiting factors. Meta-analysis
can overcome some of these limitations, if the studies under
consideration are well designed, if not conclusive.
Obesity, African Ancestry, and the Frequency
of Myeloma
Thereareotherquestionsthathavearisenaroundtheroleof
obesity and the risk for hematological malignancies. One is
the greater prevalence of obesity in Americans of African
descent and whether that explains, in part, the higher inci-
dence of myeloma in that group (1.8-fold that of Ameri-
cans of European ancestry in the U.S.). Differences in the
normalregulationofthesteady-stateimmunoglobulinlevel
between persons of European and African descent [55] and
the independent link between both obesity and African de-
scent and the incidence of essential monoclonal gammopa-
thy suggest a biological rather than environmental
explanationforthehigherrateofdiseaseamongAmericans
of African ancestry.
The Obesity Epidemic and the
Lymphoma Epidemic
Another potential association is the, as yet unexplained,
marked increase in the annual incidence of lymphoma
tracked in the U.S. over the past 40 years, but probably ini-
tiated closer to 60 years ago based on European data. The
increase in incidence of non-Hodgkin’s lymphoma has
beenabout1.8-foldoverthelast40years.TheSurveillance,
Epidemiology, and End Results program of the U.S. Na-
tional Cancer Institute has only been tracking cancer inci-
dence and mortality for approximately 40 years, whereas
several European countries have been doing so for a longer
period. Does the increased incidence of obesity account for
some of that increase? Current data do not permit a defini-
tive conclusion, but obesity is probably not a principal ex-
planation because the increase over the last 40 years has
been found among all lymphoma subtypes and the data for
obesity in that regard remain equivocal.
Weight Loss and the Prevention of Cancer
One of the important observations that adds more evidence
to the obesity–cancer relationship is the data indicating a
decrease in cancer incidence in persons who have had suc-
cessful bariatric surgery [56] or who have undergone sus-
tained weight loss from exercise and decreased caloric
intake [57]. This effect has not been shown for hematolog-
ical malignancies to my knowledge.
Possible Metabolic Effects of Obesity and
Cancer Onset
The Fat Cell as an Endocrine Gland
The effects of obesity can be discriminated into two patho-
genetic categories: the result of the greater mass of fat itself
and the result of an expansion of the endocrine function of
the enlarged and higher numbers of fat cells and the effects
of these endocrine changes on target tissues (e.g., increased
plasma leptin, insulin, insulin growth-factor [IGF]-1, an-
drogens,estrogens,IL-6,andtumornecrosisfactor-)[58].
The former mechanism, for example, has been linked to a
higherincidenceofadenocarcinomaoftheesophagusinthe
obese because of the greater frequency and severity of gas-
tric reflux, whereas the higher incidence of carcinoma of
the breast and uterus, for example, may be in part a reflec-
tion of elevated estrogen levels resulting from obesity.
Laboratoryinvestigatorshavefoundthatanimalsinwhich
energyintakeisreducedtoabout60%oftheintakeofanimals
that are fed as much as they want have a considerably lower
incidence of cancer than the animals in the comparison group
without restricted intake. This predisposing factor apparently
holdstrueforviral,chemical,andspontaneouscarcinogenesis.
Evidence from studies in humans has been largely compatible
with these laboratory findings and indicates that obesity in-
creases the risk for a wide spectrum of sites and types of tu-
mors [3–10, 12, 13, 59].
The elevation of several hormones correlated with
greater adiposity has been associated with cancer cell
growth. IGF-1 enhances the growth of cell lines of several
types cancers [3, 60]. The IGF-1 receptor is overexpressed
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sionofthep53gene.IGF-1issynthesizedintheliverandis
influenced by growth hormone and carbohydrate and pro-
tein intake. Fat cells are an important secondary source of
IGF-1. Its plasma half-life and local availability in tissues
aredependentonafamilyofbindingproteins.IGF-1fosters
cell cycle progression from the G1 to S phase in normal and
cancer cells. It is thought to mediate the anticancer effects
of calorie restriction, whereas cells with high levels of
IGF-1 receptor are susceptible to its antiapoptotic effect.
Hyperinsulinemiaandinsulinresistanceincreasecancer
riskatsometissuesitesandareinducedbyadiposity[3,60,
61].Itisnotknownwhethertheseeffectsaredirectandme-
diated through the insulin receptor or whether they act by
stimulation of IGF-1. The downstream targets in signaling
pathways that control cell growth and survival include
phosphoinositide 3-kinase/Akt, one of the most commonly
aberrant pathways in epithelial tumors. Often, the activa-
tion of this signaling pathway is associated with an activa-
tion of the mammalian target of rapamycin signal, a potent
effector of cell proliferation and resistance to apoptosis.
Leptin, a peptide hormone secreted principally by fat
cells, regulates appetite through hypothalamic receptors
and neuroendocrine pathways so as to maintain the amount
of body fat tissue, albeit imperfectly. Leptin can stimulate
neoplastic cells, but not normal cells, in culture and higher
levels have been associated with colon and prostate carci-
noma. In animal models, it fosters angiogenesis and tumor
invasion [3, 60, 61]. It has been associated with enhanced
growth of acute promyelocytic leukemia cells [23].
Adiponectin, a peptide hormone produced by adipocytes,
is a regulator of insulin sensitivity and thereby carbohydrate
and lipid metabolism. Paradoxically, adiponectin is decreased
in extreme obesity. Its potential role in cancer causation is un-
clear [60, 61]. Lower adiponectin levels, controlling for age,
gender, BMI, and leptin, have been associated with a lower
risk for myeloma [62].
Adiposetissueisaprincipalsiteofestrogensynthesisin
postmenopausal women and men. Aromatase in fat cells
converts androgenic precursors (e.g., androstenedione)
from the adrenal and gonads to estrone and estradiol. This
process is a function of fat cell mass and can, for example,
significantly increase estrogen levels in postmenopausal
women and men [63]. This effect may play an important
role in the relationship between obesity and endometrial
and postmenopausal breast cancer [3, 60, 61, 63].
IL-6 has an essential role in the initial progression of
myeloma cell tumors. IL-6 triggers proliferation of my-
elomacellsthroughtheRAS–mitogen-activatedproteinki-
nase signaling pathway and it promotes myeloma cell
survival through activation of the signal transducer and ac-
tivator of transcription pathway’s role in regulating the ex-
pression of BCL-2 antiapoptotic proteins. Fat cells are an
additional source of IL-6 and may provide a link between
adiposity and a higher risk for myeloma. In this case, we
have a quantifiable proportion of persons with a nonpro-
gressive clone (essential monoclonal gammopathy) with
the potential to undergo clonal evolution into an aggressive
plasma cell neoplasm. No data, however, exist to indicate
that obesity plays a role in the 1% of patients per year with
monoclonalgammopathywhoprogresstoalymphomaora
progressive plasma cell neoplasm.
Other Mechanisms Linking Obesity to Cancer
Other hypothetical links between obesity and the neoplastic
transformation of tissue cells have included obesity-related
hypoxia (e.g., melanocyte transformation), migrating adipose
stromal cells (neovascularization, favoring tumor progres-
sion), shared genetic susceptibility (common genetic predis-
position to obesity and cancer), obesity-related inflammation,
obesity-related increase in oxidative stress, and nuclear-factor
 B as a mediator of insulin resistance [3]. Obesity has also
beenshowntoimpairimmuneresponses,anotherpossiblelink
to non-Hodgkin’s lymphoma [27].
Amongtheglobalquestionsthatremaintobeanswered,
assuming a role for obesity in the causation of hematologi-
calcancers,includewhethertheeffectisinductiveorselec-
tive, or perhaps both. That is, can the endocrinological,
metabolic, and immunological changes incurred by obesity
resultingeneticorepigeneticchangesinatissuecellresult-
ing in a malignant transformation or does the obese milieu
permit the selection of transformed cells that had been in a
state of dormancy?
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